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associated with local immunoglobulin hyperproduction and the
presence of IgE antibodies against Staphylococcus aureus
enterotoxins (SAEs). Aspirin-exacerbated respiratory disease is
a severe form of chronic rhinosinusitis with nasal polyps in
which nearly all patients express anti-SAEs.
Objectives: We aimed to understand antibodies reactive to
SAEs and determine whether they recognize SAEs through
their complementarity-determining regions (CDRs) or
framework regions.
Methods: Labeled staphylococcal enterotoxin (SE) A, SED, and
SEE were used to isolate single SAE-specific B cells from the
nasal polyps of 3 patients with aspirin-exacerbated respiratory
disease by using fluorescence-activated cell sorting.
Recombinant antibodies with ‘‘matched’’ heavy and light chains
were cloned as IgG1, and those of high affinity for specific SAEs,
assayed by means of ELISA and surface plasmon resonance,
were recloned as IgE and antigen-binding fragments. IgE
activities were tested in basophil degranulation assays.
Results: Thirty-seven SAE-specific, IgG- or IgA-expressing
B cells were isolated and yielded 6 anti-SAE clones, 2 each for
SEA, SED, and SEE. Competition binding assays revealed that
the anti-SEE antibodies recognize nonoverlapping epitopes in
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http://dx.doi.org/10.1016/j.jaci.2016.06.066basophil degranulation, and IgG1 or antigen-binding
fragments of each anti-SEE enhanced degranulation by the
other anti-SEE.
Conclusions: SEEs can activate basophils by simultaneously
binding as antigens in the conventional manner to CDRs and as
superantigens to framework regions of anti-SEE IgE in
anti-SEE IgE-FcεRI complexes. Anti-SEE IgG1s can enhance
the activity of anti-SEE IgEs as conventional antibodies through
CDRs or simultaneously as conventional antibodies and as
‘‘superantibodies’’ through CDRs and framework regions to
SEEs in SEE–anti-SEE IgE-FcεRI complexes. (J Allergy Clin
Immunol 2016;nnn:nnn-nnn.)
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Staphylococcus aureus and its superantigens are implicated in
the intense inflammatory processes of the upper and lower air-
ways in patients with allergic diseases.1 These superantigens,
in particular Staphylococcus aureus enterotoxins (SAEs), are
strongly associated with chronic rhinosinusitis with nasal polyps
(CRSwNP), particularly in the subpopulation of patients with
aspirin-exacerbated respiratory disease (AERD), as well as those
with allergic rhinitis, asthma, and atopic dermatitis.2-5 SAEs are a
family of structurally related proteins comprising different
serological types, such as staphylococcal enterotoxin (SE) A,
SEB, SEC, SED, and SEE (up to SEU) and toxic shock syndrome
toxin 1 (TSST-1).6 SAEs are potent T-cell superantigens, causing
polyclonal activation of up to 25% of certain T-cell populations
by interacting with a common b-chain structural framework
region in the T-cell receptor (TCR),7,8 rather than the
complementarity-determining region (CDR), which recognizes
specific antigenic peptides bound to MHC. The activity of SEA
and SED on B cells in vitro suggests that they can also act as
B-cell superantigens by binding to the common structural
framework regions in the immunoglobulin heavy-chain variable
region (VH) domains shared by immunoglobulins with
different CDRs,9-11 as previously shown for staphylococcal
protein A (SpA).12-14 This might increase the polyclonality of
the B-cell repertoire in patients with CRSwNP and allow
S aureus to escape immune surveillance.15,16
Nasal polyps in patients with CRSwNP are inflammatory
outgrowths of the paranasal sinus mucosa, which are generally
characterized by TH2 inflammation, local immunoglobulin
production, and eosinophil infiltration driven by IL-5 and
eotaxin.17-20 Up to 100% of patients with AERD express
anti-SAE IgEs in their nasal polyp homogenates and often have
a higher prevalence of comorbid asthma and eosinophilic1
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2 CHEN ET ALAbbreviations used7-AAD: 7-Aminoactinomycin DAERD: Aspirin-exacerbated respiratory diseaseCDR: Complementarity-determining regionCRSwNP: Chronic rhinosinusitis with nasal polypsFab: Antigen-binding fragmentFACS: Fluorescence-activated cell sortingSAE: Staphylococcus aureus enterotoxinSE: Staphylococcal enterotoxinSpA: Staphylococcal protein ASPR: Surface plasmon resonanceTCR: T-cell receptorTSST-1: Toxic shock syndrome toxin 1VH: Heavy-chain variable regionVL: Light-chain variable regioninflammation,17,21-23 and IgEs from nasal polyps activate
basophils in response to allergens and SEB in vitro.15 SEB acts
as a human T-cell superantigen in vivo to cause the symptoms
of atopic dermatitis.24 Basophils isolated from patients with
atopic dermatitis with anti-SAE IgE in their sera, but not those
from healthy control subjects, were responsive to SAEs.25
Although anti-SAE IgE can be detected in the circulation ofFIG 1. Isolation of SAE1 B cells from nasal polyps by m
biotinylated SEA, SED, and SEE and phycoeryth
anti-CD19, and 7-AAD. A, The lymphocyte population w
scatter; SSC, side scatter. B, Live B cells were identifie
one (FMO) control (Fig 1, C) and no SAE control (Fi
AAD2 cells, which constituted 0.25% of the total B-cell
that the cells were stained with all fluorescent antibodie
but without biotinylated SAEs, whereas FMO control in
streptavidin-FITC.patients with CRSwNP, B cells expressing this IgE are confined
to the nasal mucosa, suggesting a role in sinonasal inflamma-
tion.17 Whether the SAEs bind to CDRs, framework regions, or
both is addressed in the present work.
Antibody production in nasal polyps of patients with
CRSwNP is driven by local activation and differentiation into
plasma cells of B cells on exposure to various aeroallergens
and microbial antigens.26,27 Thus nasal polyps removed from
patients with AERD provide a unique source of tissue to study
how SAEs can shape the local antibody repertoire. In the first
study of this kind, we used an efficient single-cell RT-PCR
method to clone and express antibodies from single SAE-
specific B cells isolated from the nasal polyps of 3 patients
with AERD and tested their primary function in effector cell
activation.METHODS
Patients’ samples
Nasal polyps and sera were collected from 3 patients with AERD
(HPK-014, HPK-016, and HPK-018) at the Royal National Throat, Nose
and Ear Hospital, London, United Kingdom. The patients were male, with
a mean age of 56 years. Only patient HPK-014 had positive skin prick
test responses to aeroallergens. The ethical committee representingeans of FACS. Cells were labeled with a mixture of
rin-coupled anti-CD138, allophycocyanin-coupled
as selected for size and granularity. FSC, Forward
d as CD1917-AAD2 cells. C-E, Fluorescence minus
g 1, D) were used to select SAE1CD191CD13827-
population (Fig 1, E). The No SAE control indicates
s and streptavidin–fluorescein isothiocyanate (FITC)
dicates cells stained with all antibodies but without
FIG 2. Six of the expressed antibodies exhibited SAE binding. The cleared supernatants collected from 293T
cells, separately transfectedwith40 IgG1expressionplasmids,were tested for reactivitywithSEA,SEB,SEC1,
SED, SEE, TSST-1, and ovalbumin (OVA) bymeans of ELISA. An antibodywith specificity to a particular SAE
was identifiedwith an absoluteODvalue greater than that of the than control IgG. The antibodies selected for
further studies are shown in boldface. Control IgG is a human IgG1 with VH4 and Vk. We expected to select
only high-affinity binders by using ELISA because of the low sensitivity of this assay.
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and all patients provided written informed consent before the study
commenced.Measurement of IgE to SAEs in sera and nasal polyp
homogenates
Detailed methods for processing sera and nasal polyp homogenates are
available in the Methods section in this article’s Online Repository at
www.jacionline.org. All sera from blood samples and homogenates from
nasal polyps were assayed for total IgE and specific IgE to SEA, SEB,SEC1, SED, SEE, and TSST-1 by using the UniCAP system (Phadia,
Uppsala, Sweden; see Table E1 in this article’s Online Repository at
www.jacionline.org).
Single B-cell sorting by using fluorescence-
activated cell sorting and single-cell RT-PCR of
immunoglobulin cDNA
Single-cell suspensions from frozen nasal polyp samples were prepared by
1 hour of digestion with 1 mg/mL hyaluronidase (Sigma-Aldrich, St Louis,
Mo) and 1U/mLLiberase TL (Roche,Mannheim,Germany) at 378C. Samples
FIG 3. Specificity and high affinity of anti-SEE and anti-SEA antibodies. A-C, Recombinant IgG1 antibodies
1G2, 203, and 1F3 at indicated concentrations were tested for binding to SEA, SEB, SEC1, SED, SEE, and
TSST-1 by using ELISA. D-F, Binding kinetics were characterized by means of SPR with biotin-labeled
SEE or SEA immobilized on a streptavidin-coated sensor chip. Purified antibodies were injected at the
indicated concentrations, followed by dissociation.
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B cells were sorted by means of fluorescence-activated cell sorting (FACS)
into 96-well PCR plates for cDNA synthesis and immunoglobulin expression
cloning as IgG1 (Fig 1). Full details of the cloning and expression strategy are
available in Fig E1 and Table E2 in this article’s Online Repository at
www.jacionline.org.Antibody cloning, expression, and purification
SEA-, SED-, and SEE-specific antibodies were expressed in human
embryonic kidney 293T cells (ATCC, Manassas, Va) as IgG1. Large-scale
production of IgE, IgG1, and antigen-binding fragments (Fabs) was carried
out with Expi293 cells (Invitrogen, Carlsbad, Calif). The IgG1 antibodies
were purified by means of protein A–Sepharose (GE Healthcare, Pittsburgh,
Pa), the IgE antibodies by omalizumab-coupled NHS-activated Sepharose
(GE Healthcare), and the Fabs by LambdaFabSelect agarose (GEHealthcare).
Anti-SAE IgG1 antibodies were identified in culture supernatants by means of
routine ELISA (Fig 2), and their purity was estimated bymeans of SDS-PAGE
under reducing conditions (see Fig E2 in this article’s Online Repository at
www.jacionline.org). Further details are available in the Methods section in
this article’s Online Repository.Sequence analysis of the monoclonal
immunoglobulin genes
Immunoglobulin gene sequences were analyzed by using the IMGT/
V-Quest tool,28 allowing identification of their clonal signatures (unique
CDR3 sequences); germline V, D, and J genes; and somatic mutations.
Sequences are available in GenBank (http://www.ncbi.nlm.nih.gov/
genbank), and their accession numbers are listed in Table E3 in this article’s
Online Repository at www.jacionline.org.
Surface plasmon resonance
Surface plasmon resonance (SPR) with a Biacore T200 instrument (GE
Healthcare) was performed to determine binding specificity, kinetics, and
affinity of the antigen-antibody interactions. Further details are available in the
Methods section in this article’s Online Repository.
Basophil degranulation assay
Degranulation of cells of the rat basophilic cell line RBL SX-38, which
stably expresses thea,b, and g chains of human FcεRI,29 was used as a routine
method to measure the functionality of the SAE-specific antibodies. Further
details are available in the Methods section in this article’s Online Repository.
FIG 4. Anti-SAE IgEs mediate SAE-induced basophil degranulation. A-C,
RBL SX-38 cells were sensitized with anti-SEA IgE 1B6 or 1F3 (Fig 4, A),
anti-SED IgE 1A4 or 2D6 (Fig 4, B), or anti-SEE IgE 1G2 or 203 (Fig 4, C)
and stimulated by the cognate SAE or anti-IgE as a positive control.
D, RBL SX-38 cells were sensitized with the indicated anti-SAE IgEs and
stimulated with the indicated SAEs. Degranulation was assayed based on
b-hexosaminidase release.
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Cloning of anti-SAE antibodies
Three patients with AERD, HPK-014, HPK-016, and
HPK-018, with titers of specific anti-SAEs in their serum or
nasal polyp homogenate were studied (see Table E1). Specific
IgEs to 6 common SAEs (SEA, SEB, SED, SEE, SEC, and
TSST-1) were detected in all 3 homogenate samples and in the
serum of patient HPK-018 and to 3 SAEs (SEA, SEE, and
TSST-1) in the serum of patient HPK-14, whereas none were
detected in the serum of patient HPK-016. Percentages of the
anti-SAE IgEs were approximately 10-fold higher in the
homogenates compared with the sera, ranging from 0.38% to
2.35% and 0.03% to 0.31%, respectively (see Table E1).
Viable SAE-positive B cells (SAE1CD191CD1382
7-aminoactinomycin D [7-AAD]2) identified by means of
FACS (Fig 1) were sorted into individual wells of 96-well
plates. SAE-bound B cells accounted for 0.18%, 0.08%, and
0.25% of the nasal polyp B-cell population of patients
HPK-014, HPK-016, and HPK-018, respectively (see Table
E4 in this article’s Online Repository at www.jacionline.org).
Matched immunoglobulin VH and light-chain variable region
(VL; k or l) DNA pairs were amplified from the cDNAs of
37 SAE1CD191CD1382 single B cells (18 from patient
HPK-014, 6 from patient HPK-016, and 13 from patient
HPK-018; see Fig E1). Of these 37 VH sequences obtained,
23 were from g chains, and 14 were from a chains. No VH
sequence was obtained from ε chains. The VH genes used in
these 37 VH sequences consisted of 12 VH1 (32.43%), 13
VH3 (35.14%), 6 VH4 (16.22%), 5 VH5 (13.51%), and 1
VH6 (2.7%) sequences. Three (HPK-014_2D6, HPK-
018_2A11, and HPK-018_2C10) of the 37 B cells expressed
both a k and a l chain. Of 40 VL sequences obtained, 25
were from the l chain, and 15 were from the k chain. All
37 B cells represented different clones ascertained by their
unique CDR-H3 sequences (BioProject ID: PRJNA347912;
https://www.ncbi.nlm.nih.gov/bioproject). We expressed all 40
of the putative SAE-specific matched variable regions as
human IgG1 antibodies.
Identification and sequence analyses of anti-SAE
antibodies
All 40 antibodies, expressed as IgG1, were assayed for the 6
SAEs detected in nasal polyp homogenates by means of
ELISA. Only SEA-, SED-, and SEE-specific antibodies
could be identified, which is consistent with screening the
B cells for only these specificities. Two anti-SEA antibodies,
HPK-018_1B6 (IgA1, IGHV1-46) and HPK-016_1F3 (IgG1,
IGHV1-69); 2 anti-SED antibodies, HPK-014_1A4 (IgA2,
IGHV3-34) and HPK-018_2D6 (IgA1, IGHV3-49); and 2
anti-SEE antibodies, HPK-014_1G2 (IgA1, IGHV3-30) and
HPK-016_203 (IgG4, IGHV5-51), were identified (Fig 2). The
germline immunoglobulin variable genes and isotypes used by
those 6 antibodies are shown in Table E3. We refer to these
antibodies below as the anti-SEA antibodies 1B6 and 1F3, the
anti-SED antibodies 1A4 and 2D6, and the anti-SEE antibodies
1G2 and 203.
FIG 5. Anti-SEE antibodies bind to distinct nonoverlapping epitopes. A, 1G2 IgG1 (250 nmol/L) was injected
onto a sensor chip coated with SEE for 3 minutes, immediately followed by a 3-minute injection of either
running buffer (black), 500 nmol/L 1G2 IgG1 (blue), or 100 nmol/L 203 IgG1 (red). B, After regeneration of
the chip by using glycine-HCl (pH 2.5), the experiment was performed in reverse, with a 3-minute binding
of 100 nmol/L 203 IgG1, followed by a 3-minute injection of either buffer (black), 500 nmol/L 203 IgG1
(red), or 100 nmol/L 1G2 (blue).
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SAE antibodies are shown in Table E3. A higher frequency of l
light chains (5/6) was found when compared with that in human
peripheral blood B cells (1/5).30 Sequence alignments of 6
antibodies against their most closely related germline VH and
VL gene sequences revealed a relatively high frequency of amino
acid replacements in framework regions of VH and VL
chains (see Fig E3 in this article’s Online Repository at
www.jacionline.org).Specificity and affinity of purified anti-SAE
antibodies
ELISA was used to determine the specificity of the purified
recombinant IgG1 antibodies with the SAEs (Fig 3, A-C, and
results not shown). The 1G2 and 203 antibodies were specific
for SEE, although both displayed cross-reactivity with SEC1
(27% amino acid sequence homology with SEE) to a different
extent rather than the more homologous SEA and SED (81%
and 54% sequence homology with SEE, respectively).31 1F3
was specific for SEA but was not cross-reactive with SEE. All
3 antibodies exhibited high affinity for their cognate SAEs,
demonstrating low nanomolar binding affinities, as measured
from the kinetics of interaction with specific SAEs by using
SPR (Fig 3, D-F).Anti-SEE IgE mediates SEE-induced basophil
degranulation
The g1 chain constant region of the IgG1 antibodies was
substituted with the human ε constant region and the resulting
IgEs were expressed and purified to examine the activities of
the corresponding anti-SAE IgEs (see Fig E2, B). Basophil
degranulation activities of the 6 anti-SAE IgEs in the presence
of the cognate SAE are shown in Fig 4.
Conventional antigen binding through CDRs to 2 identical
receptor-bound monoclonal IgE molecules, each of which
recognizes a single epitope in a monomeric antigen, should notinduce cross-linking of FcεRI on the surfaces of basophils to
cause basophil degranulation. The anti-SEAs (Fig 4, A) and the
anti-SEDs (Fig 4, B) behaved as expected, whereas both
anti-SEE IgEs, 1G2 and 203, were active in this assay (Fig 4,
C). Basophil activation would require either 2 identical epitopes
in the SEE because it formed a dimer like SED32 or 2 independent
epitopes in an SEE molecule if it were a monomer. A recent
crystal structure of SEE in a complex with TCR revealed a mono-
meric structure.33 Thus we conclude that SEE has 2 distinct and
nonoverlapping epitopes that explains this activity; this is
illustrated and discussed below. SEC1 did not trigger 1G2 or
203 IgE-mediated basophil degranulation, although both show
cross-reactivity to SEC1 (Fig 4, D).Anti-SEE antibodies bind to nonoverlapping
epitopes on SEE
To map the epitopes of anti-SEE 1G2 and 203 antibodies on
SEE, we carried out sandwich binding assays using ELISA and
SPR. ELISA revealed that saturation of the 1G2 binding site,
which was achieved through addition of SEE to immobilized 1G2
Fab and IgE, did not prevent binding of 203 IgG1 (see Fig E4 in
this article’s Online Repository at www.jacionline.org). Also,
SPR revealed that binding of saturating concentrations of 1G2
IgG1 to immobilized SEE did not prevent the simultaneous
binding of soluble 203 IgG1 (Fig 5, A). The reverse was also
observed: after saturating all of the 203 binding sites on
immobilized SEE, 1G2 IgG1 could still bind with high
affinity (Fig 5, B). Both ELISA and SPR assays confirmed that
the 2 anti-SEE antibodies bind to nonoverlapping epitopes on
SEE.Anti-SEE IgG1 modulates IgE-mediated
degranulation
The different anti-SEE isotypes, IgE and IgG1, were tested in
pairwise combinations in basophil degranulation assays to
characterize their interplay. As expected, because of competition
FIG 6. The unrelated anti-SEE IgG1 or Fab enhances anti-SEE IgE–mediated
basophil degranulation. RBL SX-38 cells were sensitized with anti-SEE or
anti-SEA IgE antibodies and stimulated with SEE in the presence of
anti-SEE (11G2/1203) or anti-SEA (11F3) IgG1 (A) or Fab (B). Dotted lines
represent positive (upper; anti-IgE) and negative (media only) controls.
Degranulation was assayed based on b-hexosaminidase release.
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degranulation of basophils sensitized with the 1G2 IgE, and the
203 IgG1 inhibited degranulation of basophils sensitized with
the 203 IgE (Fig 6, A).34,35 As also expected, the IgG1 that
recognized the nonoverlapping epitope on IgE enhanced
degranulation (Fig 7, A) by cross-linking 2 SEE molecules bound
to adjacent receptor-bound IgE molecules; this is illustrated
below in Fig 5, B. The 1F3 antibody, which is specific for SEA,
had no such effects, demonstrating that antigen specificity is
crucial for the modulation of IgE activity by IgG1.Paradoxical enhancing activity of anti-SEE Fabs
We repeated the pairwise assays by using the 2 anti-SEE IgG1
Fabs (Fig 6, B). As expected, the Fabs exhibited the sameinhibitory activity as the whole IgG1 antibodies (because of
competitive inhibition) when Fab and IgE were of the same
specificity. Cross-linking of adjacent IgE-SEE complexes on the
basophil surface cannot occur with a monomeric Fab, even one
that binds to the nonoverlapping epitope. Paradoxically, the Fab
recognizing the nonoverlapping epitope retains the enhancing
activity of the whole IgG1 (Fig 6, B).
Fig 7, C, illustrates the mechanism by which receptor
cross-linking can occur. We suggest that high-affinity binding
of receptor-bound anti-SEE IgE to SEE through its CDRs to the
epitope represented in green (Fig 7, C) facilitates subsequent
low-affinity binding through a site on SEE, which is represented
in red, that binds to a framework region of an adjacent IgG (or
Fab) that recognizes a nonoverlapping SEE epitope, which is
represented in blue. We call such an antibody, in principle of
any isotype that acts synergistically to enhance IgE effector
functions, a ‘‘superantibody.’’DISCUSSION
Several human mAbs against specific allergens have been
obtained from allergic patients by means of phage display,36-40
EBV transformation of PBMCs,41 or single-cell RT-PCR.34 In
addition, many groups have generated anti-SEB mAbs by using
either mouse hybridomas or phage display and pursued their
use as therapeutic agents.42,43 In earlier work we produced a
recombinant allergen (Phl p 7)–specific antibody with the native
(‘‘matched’’) heavy and light chain by using single-cell PCR.34 To
the best of our knowledge, the present work is the first report of
recombinant anti-SAE antibodies containing matched heavy
and light chains cloned by using single-cell RT-PCR. We
produced 6 anti-SAE antibodies that bind to SAEs with high
affinity: 2B6 and 1F3 for SEA, 1A4 and 2D6 for SED, and 1G2
and 203 for SEE. The VH regions of 1F3 and 203 were derived
from single IgG-expressing B cells and 1B6, 1A4, 1G2, and
2D6 from single IgA-expressing B cells, which were present in
nasal polyps from 3 patients with CRSwNP (see Table E3). The
antibodies were first expressed as IgG1 and then converted to
IgE and Fab.
We began with the hypothesis that SAEs can act as B-cell
superantigens, as well as T-cell superantigens. Indeed, this
suggestion has often been made before. It is consistent with the
evidence that SEA and SED bind weakly to immunoglobulins
bearing VH3 and VH4, respectively.10,11 Several authors have
demonstrated the overabundance of VH5 in IgE, suggesting that
such a B-cell superantigen can recognize members of this VH
family.44-47 Low-affinity and promiscuous binding to the TCR
variable b (Vb) chains are characteristics of T-cell superantigens,
which include SEA, SED, and, notably, SEE.7,8 SEE binds to 6
different human Vb chains.48 We have shown that SEE can
indeed behave as a B-cell superantigen by interacting with IgE
molecules both conventionally through CDRs and unconvention-
ally through framework regions (Fig 7, A).
ELISA assays used to select the 6 antibodies described in the
present study (Fig 3) would not have detected weak binding of
SAEs to the framework regions. However, strong binding of
SAEs to the CDRs in the context of a cell (Fig 2) would facilitate
weak binding to the framework regions because of an increase in
avidity. Binding of SAEs to the framework regions as well as
CDRs of BCRs can contribute to somatic hypermutation and
affinity maturation of antibodies. Coker et al46 found 75% of
FIG 7. Schematic representation of proposed antibody and ‘‘superanti-
body’’ activities. A, A monomeric SEE molecule cross-links 2 FcεRI-bound
IgE molecules on the surface of a basophil (receptor not shown) through
2 epitopes: the green site is recognized conventionally by the CDRs of the
IgE antibody, and the red site interacts with the framework regions of the
IgE V region in a superantigen manner. B, An IgG1 antibody that recognizes
a nonoverlapping blue epitope cross-links 2 FcεRI-bound IgEmolecules that
recognize the green epitope; both blue and green epitopes are recognized
conventionally by the CDRs. C, Because the IgG1 Fab (highlighted in darker
blue) can also cross-link FcεRI-bound IgE, we propose that 2 monomeric
=
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expressed by B cells in the nasal mucosa, which are often exposed
to S aureus commensal infections.46 Superantigen-driven
selection at the stage of local affinity maturation might explain
the high frequency of mutations in the framework regions of
our cloned anti-SAEs (see Fig E3).
Due to the real-world limitations of the experimental methods
used in this study, we have not obtained definitive evidence for the
proposed interactions (Fig 7). First, IgE-expressing antibodies
were not among the 40 recombinant antibodies we expressed;
this was not surprising because of the extremely low abundance
of IgE- compared with IgG- and IgA-expressing B cells.49
Second, although we have shown that IgG-expressing B cells
undergo local switching to IgE in nasal polyps from patients
with CRSwNP and in the respiratory tract mucosa in patients
with allergic diseases,50-53 1G2 and 203 antibodies came from
different patients. We would have needed IgE related to at least
1 of them and both antibody isotypes from the same subject to
prove the existence of superantibodies in this AERD cohort.
Nevertheless, in unpublished work using next-generation
sequencing of B-cell repertoires in nasal polyps, we have
observed as many as 17/10,000 IgE sequences related to IgG or
IgA. In the B-cell repertoire of patient HPK-014, we were able
to identify IgE relatives of 2 recombinant IgG1 antibodies (A:
HPK-014_1A6 and B: HPK_014 2A8; see Fig E5 in this article’s
Online Repository at www.jacionline.org), although these 2 IgG1
clones were not among the 6 clones that exhibited high affinity for
the SAEs (Fig 3).
One of the antibodies, 203, was originally an IgG4 and, interest-
ingly, expresses IGHV5-51, the only of 2 VH5 family members
that is overexpressed in IgE (Wu et al, unpublished results) and
a candidate for binding in a superantigen-likemanner.46 The other
antibody, 1G2, was originally an IgA1 and expresses a member of
the VH3 family (IGHV3-30, see Table E3). The CDRs differ
between 203 and 1G2, and therefore it might be that SEE binds
promiscuously to both VH5 and VH3 framework regions.
Structural studies are required to define the epitopes in SEE.
It was previously shown by using x-ray crystallography that
SpA is recognized by a rheumatoid factor antibody in a
superantigen-dependent manner, in which SpA interacts with
the framework residues of the VH3 domain.14We believe the anti-
SEE superantibodies presented here might be the first antibodies
shown to have both conventional antigen- and superantigen-
binding sites and thus to have superantibody activity.
The ability of the anti-SEE IgG1 and its Fabs to inhibit the
activity of basophils sensitized by the related IgE resembles the
blocking activities of IgG4 or IgA in specific allergen
immunotherapy.34,35,54 Blocking IgG antibodies have been
developed by many groups for therapeutic use as antitoxins.
Nearly all antitoxin antibodies and all isolated anti-SEB anti-
bodies are blocking, as opposed to enhancing, antibodies.42,43,55SEE molecules can affect this: one is recognized conventionally through
the 2 nonoverlapping (green and blue) epitopes by 2 unrelated anti-SEEs,
and the other involves the superantigen site (red). Although the
cross-linking ability of the Fab reveals the interactions that underpin this
proposed mechanism, the whole antibody can act not only in the manner
depicted in Fig 7, B, but also that shown in Fig 7,C. This antibody, exhibiting
the ability to recognize 2 SEEmolecules simultaneously through both CDRs
and framework regions, we call a ‘‘superantibody.’’
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for efficacy in treating infections with S aureus.56,57 Whether
anti-SEE IgGs from the present study might be similarly
efficacious could be determined, but a combination of
anti-SAEs might be even more efficacious than any single
anti-SAE.
To the best of our knowledge, 1G2 and 203 are the first
examples of enhancing anti-SAE antibodies. However, there is a
precedent in the case of the antibody BAB2 against a dominant
birch pollen allergen, Bet v 1.58 BAB2 and, notably, its Fab
enhanced binding of Bet v 1 to IgE and caused immediate-type
hypersensitivity reactions in human skin. The authors suggested
that enhancing antibodies could account for the failure of specific
allergen immunotherapy.58-60 Although enhancing antibodies are
relatively rare, they might be important because their activity
might ‘‘win’’ in competition with an excess of blocking
antibodies.
In previous studies it has been demonstrated that certain
antibodies against a specific allergen are more frequently
observed than others in atopic patients; such allergens, that is,
Der p 1 and Der p 2 in patients with house dust mite allergy, are
said to be dominant allergens.61,62 These allergens usually have
multiple epitopes, allowing more extensive cross-linking of the
IgE-FcεRI complexes on effector cells. In this case noncompeti-
tive allergen-specific IgG or IgA,which are likely present inmuch
higher concentrations than IgE, might be able to enhance cell
activation if the configuration of the 2 sites and the resulting
distance between cross-linked complexes is favorable (Fig 7, B).
SEE was first documented in a case of food poisoning.63 It was
later identified as a 26.4-kDa single-chain protein belonging to the
group III superantigens (the SEA superfamily), having strong
homology to SEA and SED, as stated above. SEE has been shown
to be a potent enterotoxin and a polyclonal activator of T cells64,65
and binds promiscuously to multiple human TCR Vb chains.48
Anti-SEE IgE was demonstrated in 16.7% of nasal polyps
compared with 0% of control tissue, as well as in all nasal polyp
samples from all 3 patients with CRSwNP in the present study.17
Sequence comparison of SEA, SEC1, SED, and SEE and
inspection of the SEA and SEE crystal structures32,33 suggest
that certain surface-exposed residues could alter the electrostatic
potential or shape of the enterotoxin surface, rendering SEE and
SEC1 different from SEA and SED and thereby contributing to
the cross-reactivity of the 203 antibody.
Basophils were activated to release granular mediators by
allergens and SEB when sensitized by IgE in homogenates from
the nasal polyps of patients with CRSwNP in vitro,15 indicating
the functionality of IgE antibodies in nasal polyps. Thus the
putative anti-SEE IgEs 1G2 and 203 in patients HPK_014 and
HPK_016, together with the potential IgG4 or IgA1 precursors,
could have activated a variety of effector cells and contribute to
the proinflammatory environment in the patients’ nasal polyps.
This is compatible with evidence from the work of Gevaert
et al66 showing that omalizumab is therapeutic in patients with
CRSwNP, although an earlier study did not show efficacy.67 It
should also be noted that IgG and IgA superantibody activities
are independent of isotypes.
In summary, our results provide proof of concept that SAES
can act as B-cell superantigens and that anti-SAE antibodies of
any isotype can behave as superantibodies. We have isolated
antibodies with potential superantibody activity from nasal
polyps of patients with AERD, a highly inflammatory TH2disease. However, similar antibodies can occur in patients with
allergic diseases and asthma associated with commensal S aureus
infections and dominant allergens.
Clinical implications: Anti-SAE IgE antibodies alone or
together with IgG1 can contribute to the pathogenesis of
CRSwNP and allergic disease.REFERENCES
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METHODS
Preparation of sera and nasal polyp homogenates
Blood samples were allowed to clot at room temperature for 1 hour and
centrifuged at 2000g for 20 minutes, and serum was separated and stored at
2708C. PBS containing protease inhibitor cocktail (Roche) was added to
snap-frozen nasal polyp specimens at 1 mL per 0.1 g of tissue. Tissues
were homogenized with a TissueLyser (Qiagen, Hilden, Germany) for
2 minutes at 30 Hz until disrupted, homogenates were centrifuged at
15,000g for 20 minutes at 48C, and supernatants were collected and stored
at 2708C.
Single cell sorting by using FACS
After dispersion by means of enzymatic digestion of nasal polyps, cells
were washed with complete RPMI medium (10% FBS in RPMI medium) to
remove the enzymes, filtered through a 40-mm cell strainer, and finally
resuspended at a concentration of 1 3 106 cells/mL in FACS buffer (5%
normal goat serum [Invitrogen, Carlsbad, Calif] and 2 mmol/L EDTA in
PBS). Then cells were stained with phycoerythrin-coupled anti-CD138
(BioLegend, San Diego, Calif), allophycocyanin-coupled anti-CD19 (BD
Biosciences, San Jose, Calif), 7-AAD (eBioscience, San Diego, Calif), and
biotinylated SAEs (Toxin Technology, Sarasota, Fla) in FACS buffer.
Biotinylated SEA, SED, and SEE were simultaneously used for labeling cells
each at a concentration of 10 mg/mL and detected by means of FACS with
streptavidin–Alexa Fluor 488 (Invitrogen) at a dilution of 1:1000.
Single-cell RT-PCR
Single SAE1CD191CD13827-AAD2 B cells were directly sorted into
96-well PCR plates (Fermentas, Vilnius, Lithuania) containing 18 mL/well
of ice-cold 13 RT buffer (Invitrogen) containing 0.1% Triton-X 100,
10 mmol/L dithiothreitol, 300 ng of random hexamers (Invitrogen),
0.5 mmol/L dNTP mix (Fermentas), and 40 U of Ribolock RNase Inhibitor
(Fermentas) on a FACSAria II cell sorter (BD Biosciences). Fifty units of
Superscript III reverse transcriptase (Invitrogen) was added, and then reverse
transcriptionwas performed at 428C for 10minutes, 258C for 10minutes, 508C
for 60 minutes, and 858C for 5 minutes.
Primer nucleotide sequences to cover all known V-region genes and
reverse primers specific for k and l constant regions were as previously
described.E1 Reverse primers for g, a, and ε constant regions were Cg1
(59-GGAAGGTGTGCACGCCGCTGGTC-39), Cε1 (59-GGTTTTGTTGTC
GACCCAGTCTG-39), and Ca1 (59-TGGGAAGTTTCTGGCGGTCACG-
39) as primary primers for the first-round PCR and Cg2 (59-GTTCGGGG
AAGTAGTCCTTGAC-39), Ca2 (59-GTCCGCTTTCGCTCCAGGTCACA
CT-39), and Cε2 (59-TGGCATAGTGACCAGAGAGCGTG-39) as nested
primers for the second-round PCR, respectively. All PCRs were carried out
by proofreading Phusion DNA polymerase (Fermentas). Second-round PCR
products were sequenced after purification by using the QIAquick PCR
Purification Kit (Qiagen).
Recombinant antibody cloning and expression
Purified second-round PCR products were used as a PCR template for
amplifying DNA inserts by V-region– and J-region–specific primers contain-
ing an overhang sequence (Table E2), which are homologous to the bases at
one end of adjacent DNA fragments of pIgG1(k) or pIgG1(l) vectors.
E2
Purified DraIII/NheI- and BspEI/NheI-digested DNA fragments from
pIgG1(k) and pIgG1(l) vectors were used as a template for amplifying ‘‘back-
bone insert’’ by CL forward primers, SL-Ck1 or SL-Cl1, and the IgG leader
reverse primer SL-IgG Leader- (Fig E1 and Table E2), respectively. All PCR
products above were synthesized by using Phusion DNA polymerase and pu-
rified with the QIAquick PCR Purification Kit. The linear pIgG1(k) and
pIgG1(l) vectors were prepared by means of double digestion with DraIII/
NheI and BspEI/NheI, respectively, and purified by means of agarose gel elec-
trophoresis and gel extraction (gel purification kit, Qiagen). The assembly of
antibody expression vector was carried out by means of homologous
recombination with a Geneart Seamless Assembly Kit (Invitrogen) according
to vendor’s instructions as shown in Fig E1.
Briefly, 20 ng of paired VH and VL DNA segments, 50 ng of backbone
insert, and 100 ng of linear vector were combined with Seamless enzyme mix
and incubated at room temperature for 30 minutes. The assembly products
were immediately transformed into competent E coli (One Shot Top 10, Invi-
trogen), and transformants were analyzed for the presence of DNA inserts by
using colony PCR. The plasmid DNA of positive clones was purified and
sequenced to ensure no base mutations and correct recombination.
Human embryonic kidney 293T cells (ATCC) were seeded in 6-well plates
to produce cloned antibodies on a small scale for validating their binding
specificities. Transient transfections were performed at 80% cell confluency
by linear polyethylenimine with an average molecular weight of 25 kDa
(Polysciences, Warrington, Pa) as a transfection reagent. The cells were
cultured for 2 days before the supernatants were harvested and analyzed by
means of ELISA for SAE binding reactivity. The concentrations of recom-
binant IgG1 antibodies released into the supernatants of transfected 293T cells
were measured by means of ELISAwith human IgGQuantitation Kits (Bethyl
Laboratories, Montgomery, Tex). The g1 constant regions of SAE-specific
antibody expression vectors were replaced by the ε constant region or the
CH1 domain of the g1 constant region, to construct IgE and Fab expression
vectors, respectively.
ELISA for SAE-specific antibodies in culture
supernatants
Microtiter plates were coated with 2 mg/mL of each SEA, SEB, SEC1,
SED, SEE, and TSST-1 (Toxin Technology) or ovalbumin (50 mL/well)
overnight at 48C and blocked with 200mL of assay diluent (0.5% BSA, 0.05%
Tween-20, and 0.01% thimerosal in PBS). Bound IgG1 antibodies were de-
tected by using horseradish peroxidase–conjugated goat anti-human IgG Fc
antibody (Jackson ImmunoResearch, West Grove, Pa) and developed with
NeA-Blue TMB substrate (Clinical Science Products, Mansfield, Mass).
Basophil degranulation assay
RBL SX-38 cells were typically grown in complete MEM medium, as
previously described.E3 One day before a planned experiment, RBL
SX-38 cells were seeded at 63 105 cells/mL (500 mL/well) in 48-well plates.
After an overnight incubation, 250 mL of complete MEMmedium containing
SAE-specific IgE at 1 mg/mL was added to sensitize the cells. After a 2-hour
incubation at 378C, each well was washed twice with 500 mL of prewarmed
Tyrode buffer (135 mmol/L NaCl, 5 mmol/L KCl, 5.6 mmol/L
glucose, 1.8 mmol/L CaCl2, 1 mmol/L MgCl2, 20 mmol/L HEPES, and
0.5 mg/mL BSA, pH 7.3) and then 250 mL of Tyrode buffer containing
SAEs at 1 mg/mL or polyclonal anti-human IgE antibody (Bethyl Labora-
tories) at 3 mg/mL or 1% Triton X-100 was added to the cells. After a
30-minute incubation in a 378C incubator, culture media were collected and
subjected to centrifugation at 300g for 5 minutes at room temperature. Fifty
microliters of cleared supernatants were transferred to each well of a
96-well black OptiPlate (PerkinElmer, Waltham, Mass), and then 50 mL of
substrate solution (80 mmol/L 4-methylumbelliferyl-N-acetyl-D-glucosami-
nide [Sigma-Aldrich] in 0.1 mol/L citric acid buffer, pH 4.5) was added to
each well. The tape-sealed plate was incubated at 378C for 1 hour, and the re-
action was terminated by adding 100 mL of glycine buffer (0.2 mol/L glycine
and 0.2 mol/L NaCl, pH 10.7). The resulting fluorescence (excitation, 355 nm;
emission, 460 nm) was measured with a Victor 3 fluorescence reader
(PerkinElmer). Measured values were expressed as percentages relative to
the value of release (100%) obtained by lysing cells with 1% Triton X-100.
SPR
Purified and concentrated immunoglobulin solutions were quantifiedwith a
NanoDrop spectrophotometer (Thermo Scientific, Wilmington, Del) by using
absorbance at 280 nm, and the protein concentration was calculated with the
extinction coefficient of each antibody, whichwas predicted by conducting the
computation with a ProtParam program (http://web.expasy.org/protparam/).
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Biotin-labeled SEE and SEA were immobilized on a streptavidin-coated
sensor chip (GE Healthcare). Binding of SAE-specific IgG1 antibodies was
measured at 258C by using a 3-minute association phase and a 10-minute
dissociation phase (unless otherwise specified in the figure legend) in a
concentration series ranging from 250 to 16 nmol/L. One antibody was
injected for 3minutes, followed by a 3-minute injection of the second antibody
or buffer, to detect simultaneous binding of 2 antibodies. After regeneration
with glycine-HCl (pH 2.5), the experiment was performed in reverse. Standard
double-referencing data subtraction methods were used with a control surface
(biotin alone).
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FIG E1. Cloning strategy for constructing recombinant IgG1 expression vector. Paired VH and VL regions
from sorted single SAE-specific B cells were amplified by means of RT-PCR and sequenced as
described in the Methods section in this article’s Online Repository. The 15-bp homologous arm was
introduced by means of PCR to permit cloning into pIgG1(k) or pIgG1(l) vectors by means of homologous
recombination with the Seamless method, as described in the Methods section in this article’s Online
Repository. CL, Constant region of the light chain; JH, J region of the heavy chain; JL, J region of the light
chain; L, leader; SL, seamless.
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FIG E2. Purity of recombinant SAE-specific IgG1, IgE, and Fab antibodies. All recombinant SAE-specific IgG1
(A), IgE (B), and Fab (C) antibodies were transiently expressed in Expi293F cells and purified by means of
protein A, anti-IgE, or LambdaFabSelect affinity chromatography, respectively. Five micrograms of each
antibody was fractionated by using 12% SDS-PAGE under reducing conditions before Coomassie Blue
staining.
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FIG E3. Amino acid sequence alignment for 6 cloned SAE-specific antibodies against germline
sequences. The V genes encoding the VH (A) and VL (B) of SAE-specific antibodies were identified by using
IMGT/V-Quest. Somatic hypermutations that resulted in amino acid changes are indicated.
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FIG E4. 1G2 and 203 bind to distinct epitopes on SEE. Each well of a
96-well ELISA plate was coated with 1G2 Fab or IgE antibodies at 1 mg/mL
(50 mL/well), followed by saturating 1G2 antibody binding sites with SEE at
1 mg/mL (100 mL/well). The 1F3, 1G2, and 203 IgG1 antibodies were added
to each well, followed by incubation with peroxidase-conjugated goat
anti-human IgG/Fc.
J ALLERGY CLIN IMMUNOL
nnn 2016
10.e6 CHEN ET AL
FIG E5. Expressed single-cell IgG1 clones with IgE relatives identified by using next-generation sequencing
(NGS) of B-cell repertoire. The immunoglobulin VH gene repertoire in the nasal polyps from patient
HPK-014 was captured on the Illumina 2x300 MiSeq System and bioinformatically analyzed (manuscript
in preparation). The sequences in the HPK-014 NGS data set were aligned with the recombinant IgG1
antibodies expressed from 18 FACS-sorted SAE1 B cells (SAE1CD191CD13827-AAD2), and their clonal
relatedness was determined by using clone-specific CDR3 DNA motifs. Two clonal families were identified,
showing 2 expressed recombinant IgG1 antibodies (A: HPK-014_1A6 and B: HPK-014_2A8; Sequence ID in
blue) related to IgE (sequence ID in red) and other IgG mutants in the HPK-014 NGS data set. For illustration
purposes, not all members of the clones isolated by using NGS are shown.
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TABLE E1. SAE-specific IgEs in serum and nasal polyp homogenate
Patient ID Total IgE
Serum
Total IgE
Nasal polyp homogenate
SEA SEB SED SEE SEC TSST-1 SEA SEB SED SEE SEC TSST-1
HPK-014 89.3 0.17* (0.19%) — — 0.28 (0.31%) — 0.16 (0.18%) 26.1 0.25 (0.96%) 0.12 (0.46%) 0.1 (0.38%) 0.13 (0.5%) 0.13 (0.5%) 0.21 (0.8%)
HPK-016 53.2 — — — — — — 8.1 0.11 (1.36%) 0.11 (1.36%) 0.08 (0.99%) 0.09 (1.11%) 0.11 (1.36%) 0.19 (2.35%)
HPK-018 317 0.09 (0.03%) 0.81 (0.26%) 0.78 (0.25%) 0.13 (0.04%) 0.05 (0.02%) 0.07 (0.02%) 48 0.59 (1.23%) 0.24 (0.5%) 0.31 (0.65%) 0.27 (0.56%) 0.32 (0.67%) 0.28 (0.58%)
*Kilounits per liter was introduced to express the level of IgE.
Percentage of total IgE was the percentage of each SAE-specific IgE in total IgE.
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TABLE E2. Primers used for antibody cloning
Primer Sequence
VH cloning PCR
SL-VH1/3/5f gttgctacgcgtgtcCTGAGCSAGGTGCAGCTGGTGSAGTC
SL-VH1-3f gttgctacgcgtgtcCTGAGCCAGGTCCAGCTTGTGCAGTC
SL-VH1-18f gttgctacgcgtgtcCTGAGCCAGGTTCAGCTGGTGCAGTC
SL-VH1-24f gttgctacgcgtgtcCTGAGCCAGGTCCAGCTGGTACAGTCTG
SL-VH2f gttgctacgcgtgtcCTGAGCCAGGTCACCTTGARGGAGTCTG
SL-VH3-23f gttgctacgcgtgtcCTGAGCGAGGTGCAGCTGTTGGAGTCT
SL-VH4f gttgctacgcgtgtcCTGAGCCAGSTGCAGCTGCAGGAGT
SL-VH4-34f gttgctacgcgtgtcCTGAGCCAGGTGCAGCTACARCAGTGG
SL-VH6f gttgctacgcgtgtcCTGAGCCAGGTACAGCTGCAGCAGTCA
SL-VH7f gttgctacgcgtgtcCTGAGCCAGGTGCAGCTGGTGCAAT
Vk cloning PCR
SL-Vk1f ggctcccaggtgcacgatgtgACATCCAGWTGACCCAGTCTCC
SL-Vk2f ggctcccaggtgcacgatgtgATATTGTGATGACCCAGACTCCACTCT
SL-Vk3f ggctcccaggtgcacgatgtgAAATTGTGTTGACRCAGTCTCCAG
SL-Vk4f ggctcccaggtgcacgatgtgACATCGTGATGACCCAGTCTC
SL-Vk5f ggctcccaggtgcacgatgtgAAACGACACTCACGCAGTCTC
SL-Vk6f ggctcccaggtgcacgatgtgAAATTGTGCTGACTCAGTCTCCA
Vl cloning PCR
SL-Vl1-40/50/51f tccttgcttatgggtccggaGTGGATTCTCAGTCTGTGYTGACGCAGCC
SL-Vl1-36/44/47f tccttgcttatgggtccggaGTGGATTCTCAGTCTGTGCTGACTCAGCCA
SL-Vl2f tccttgcttatgggtccggaGTGGATTCTCAGTCTGCCCTGACTCAGCC
SL-Vl3f tccttgcttatgggtccggaGTGGATTCTTCCTATGAGCTGACWCAGCCA
SL-Vl3-19f tccttgcttatgggtccggaGTGGATTCTTCTTCTGAGCTGACTCAGGAC
SL-Vl4/5/9f tccttgcttatgggtccggaGTGGATTCTCAGSCTGTGCTGACTCAGCC
SL-Vl4-60/69f tccttgcttatgggtccggaGTGGATTCTCAGYCTGTGCTGACTCAATC
SL-Vl6f tccttgcttatgggtccggaGTGGATTCTAATTTTATGCTGACTCAGCCC
SL-Vl7/8f tccttgcttatgggtccggaGTGGATTCTCAGRCTGTGGTGACYCAGGAG
SL-Vl10f tccttgcttatgggtccggaGTGGATTCTCAGGCAGGGCTGACTCAGCC
JH cloning PCR
SL-JH1/4/5r gatgggcccttggtgctagcTGAGGAGACGGTGACCAGG
SL-JH2r gatgggcccttggtgctagcTGAGGAGACAGTGACCAGGGT
SL-JH3r gatgggcccttggtgctagcTGAAGAGACGGTGACCATTGTC
SL-JH6r gatgggcccttggtgctagcTGAGGAGACGGTGACCGTG
Jk cloning PCR
SL-Jk1r tgcagccaccgtacgTTTGATTTCCACCTTGGTCCCT
SL-Jk2r tgcagccaccgtacgTTTGATCTCCAGCTTGGTCCCT
SL-Jk3r tgcagccaccgtacgTTTGATATCCACTTTGGTCCCA
SL-Jk4r tgcagccaccgtacgTTTGATCTCCACCTTGGTCCCT
SL-Jk5r tgcagccaccgtacgTTTAATCTCCAGTCGTGTCCCTT
Jl cloning PCR
SL-Jl1r ggccttgggctgacctaggACGGTGACCTTGGTCC
SL-Jl2/3r ggccttgggctgacctaggACGGTCAGCTTGGTCC
SL-Jl6r ggccttgggctgacctaggACGGTCACCTTGGTGC
SL-Jl7r ggccttgggctgacctaggaCGGTCAGCTGGGTGC
Backbone insert cloning PCR
SL-Ck1 CGTACGGTGGCTGCACCATC
SL-Cl1 GGTCAGCCCAAGGCCAACC
SL-IgG Leader- GACACGCGTAGCAACAGCGA
Homologous sequences to the bases at one end of the adjacent DNA fragment are displayed in lower case.
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TABLE E3. Germline immunoglobulin variable gene and CDR3 sequences of cloned VH and VL pairs in the SAE-specific
antibodies
Clone name Isotype
Accession
(VH) IGHV IGHD IGHJ CDR-H3 amino acids
Accession
(VL) IGK(L)V IGK(L)J CDR-L3 amino acids
HPK-014_1A4 A (a2) KT369789 3-23 3-9 3 CAKKRRYDAVTGYLFDMW KT369790 4-1 (k) 2 CQQFYSPAPYTF
HPK-014_1G2 A (a1) KT369791 3-30 6-13 4 CARDRAQGIVAAAGTSFGYW KT369792 3-25 (l) 2 CQSGDTSGFDPDVAF
HPK-016_203 G (g4) KT369793 5-51 2-15 4 CVRHCSGGRCSSAPLDSW KT369794 6-57 (l) 3 CLSHDTTNFVF
HPK-018_1B6 A (a1) KT369795 1-46 2-8 3 CAYWGADGFDIW KT369796 1-44 (l) 3 CAVWDDSLSAWVF
HPK-018_1F3 G (g1) KT369797 1-69 3-9 4 CARGMTGYVGAYDYW KT369798 1-44 (l) 3 CASWDDRLNGPVF
HPK-018_2D6 A (a1) KT369799 3-49 2-2 4 CTTYCSSTSCQIDYW KT369800 2-14 (l) 1 CSSYTGSSGYVV
The VH and VL DNA sequences of each clone are available in GenBank (http://www.ncbi.nlm.nih.gov/genbank), and accession numbers are indicated in the table.
IGHV, Immunoglobulin heavy-chain variable region; IGKV, immunoglobulin kappa-chain variable region; IGLV, immunoglobulin lambda-chain variable region.
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TABLE E4. Cell populations of nasal polyp tissues
HPK-014 HPK-016 HPK-018
Lymphocytes* 10.1% (255,337) 7.42% (157,133) 17.2% (313,277)
Live cells (7-AAD2) 94.3% (239,878) 87.1% (136,067) 95.3% (297,159)
Live B cells (CD1917-AAD2) 20.7% (52,717) 21.1% (33,024) 29.4% (91,607)
SAE1 cells (SAE1CD1382) 0.18% (92) 0.08% (26) 0.25% (225)
Plasma cells (SAE2CD1381) 2.98% (1,573) 0.1% (34) 0.37% (339)
*164% of total nasal polyp cells.
165% of lymphocytes.
166% of total live B cells.
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